|drug361||BBV152B - Phase I Wiki||0.58|
|drug363||BBV152C - Phase I Wiki||0.58|
|drug2505||Placebo - Phase I Wiki||0.58|
|drug362||BBV152B - Phase II Wiki||0.58|
|drug1801||Late dexamethazone Wiki||0.58|
|drug2117||NHANES smell and taste tests Wiki||0.58|
|drug359||BBV152A - Phase I Wiki||0.58|
|drug360||BBV152A - Phase II Wiki||0.58|
|D000857||Olfaction Disorders NIH||0.39|
|D014777||Virus Diseases NIH||0.06|
|D045169||Severe Acute Respiratory Syndrome NIH||0.02|
There are 3 clinical trials
COVID-19 has adversely affected the healthcare system across the world. The world was not prepared for global outbreak of infectious diseases. The rapid spread of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) is enabling researchers worldwide to acquire a large amount of clinical data regarding coronavirus disease (COVID-19). The COVID-19 infection severely affects the respiratory system in the critical cases and results in mortalities. The affected people experience a dry cough, fever, breathing problems, diarrhea, muscle pain, and sore throat. Besides that, some of the evidence from Italy, South Korea, China, and Spain suggest that the COVID-19 cases also lose their senses of smell and taste resulting in alterations in those patients. The objective of this proposed study is to determine whether COVID-19 cases have Olfactory and gustatory dysfunctions as a hallmark indicator and can be used as diagnostic tools for the isolation of suspected people. Investigators are presenting a prospective proportional case-control study that is conducted to investigate the COVID-19 cases with anosmia and /or Ageusia in a university hospital in Riyadh, Saudi Arabia. The sample size of this case series would be 250 cases of suspected COVID-19 patients. The cases included in the study are analyzed prospectively to determine if the cases had a history of anosmia and /or Ageusia, and then tested for the alteration of these senses through a panel of standardized odors/taste strips. That is looked at statistically allowing us to confirm the proposed effectiveness of these tests as a diagnostic tool.
Description: to how extent alteration of smell and taste senses is related to covid19 statusMeasure: correlation of anosmia and ageusia to covid19 positive patients Time: from 1/06/2020 to 31/12/2020
Description: to determine the range of sense affection ranging from total loss to mild formMeasure: objective assessment of severity of smell and taste senses alterations in covid19 patients Time: from 1/06/2020 to 31/12/2020
Time to recover of Anosmia and / or ageusia and early corticosteroid use
Description: Time to recovery from anosmia and / or agusiaMeasure: Time to recovery Time: one to 6 weeks
Odor and taste disturbances have increased dramatically during this time of the COVID-19 pandemic. Currently, we have very little information on the demographic and clinical characteristics of the affected population, on the severity and course of the olfactory / taste loss. The main objective of this research is to analyze the epidemiological, demographic and clinical characteristics of patients suspected or already confirmed of infection with SARS-Cov2 presenting with anosmia and / or ageusia.
Data processed on January 01, 2021.